Design Therapeutics (DSGN) Enterprise Value (2020 - 2026)

Design Therapeutics has disclosed Enterprise Value across 7 years of filings, most recently posting -$222.8 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$222.8 million, up 2.98% year-over-year; the trailing twelve-month figure through Mar 2026 was -$222.8 million (up 2.98% YoY), and the FY2025 annual result was -$219.8 million, up 10.44% from the prior year.
• Enterprise Value came in at -$222.8 million for Q1 2026 at Design Therapeutics, down from -$219.8 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$206.0 million in Q3 2025 to a low of -$371.2 million in Q1 2022.
• The 5-year median for Enterprise Value is -$270.7 million (2024), against an average of -$277.8 million.
• Across the five-year window, Enterprise Value increased 18.93% in 2025 and climbed 2.98% in 2026, its largest moves.
• Design Therapeutics' Enterprise Value stood at -$330.4 million in 2022, then rose by 14.71% to -$281.8 million in 2023, then rose by 12.89% to -$245.5 million in 2024, then increased by 10.44% to -$219.8 million in 2025, then decreased by 1.35% to -$222.8 million in 2026.
• The last three Enterprise Value figures came in at -$222.8 million (Q1 2026), -$219.8 million (Q4 2025), and -$206.0 million (Q3 2025), per Business Quant data.